Ocular form of myasthenia gravis which developed as a result of chemoimmunotherapeutic treatment of locally advanced stomach cancer MSI with achievement of pCR

Immunotherapy (IT) is one of the main ways to treat solid tumors. Indications for IT become more extensive every year, and data on monitoring and treating autoimmune adverse events are accumulating. Rare complications become more common. In this clinical case, we show experience of using chemoimmunotherapy in the neoadjuvant setting of locally advanced gastric cancer with the presence of microsatellite instability and autoimmune adverse event — ocular myasthenia gravis.